Immunogenicity and Safety of an Inactivated COVID-19 Vaccine
- Conditions
- COVID-19
- Interventions
- Biological: 23-valent pneumococcal polysaccharide vaccineBiological: Inactivated COVID-19 VaccineBiological: Inactivated Hepatitis A Vaccine
- Registration Number
- NCT04953325
- Lead Sponsor
- Sinovac Research and Development Co., Ltd.
- Brief Summary
This study is a randomized, placebo-controlled and open design, phase 4 clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd. The purpose of this study is to evaluate the immunogenicity and safety of the CoronaVac in healthy population aged 18 years and older.
- Detailed Description
This study is a randomized, placebo-controlled and opened, phase 4 clinical trial to evaluate the safety and immunogenicity of an inactivated COVID-19 vaccine(CoronaVac）in healthy population aged 18 years and older . The experimental vaccine is manufactured by Sinovac Research and Development Co.,Ltd. A total of 270 healthy subjects will be enrolled, including 135 adults aged 18-59 years and 135 elderly elderly aged 60 years and older. Subjects in each age group will be divided into two groups in a ratio of 1:1. Subjects in the experimental group will receive two doses of CoronaVac on day 0 and day 28. Subjects in the control group will receive one dose of 23-valent Pneumococcal Polysaccharide Vaccine on day 0 and one dose of Inactivated Hepatitis A Vaccine on day 28.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 270
- Healthy population aged 18 years and above;
- The subjects can understand and voluntarily sign the informed consent form;
- Proven legal identity.
- History of SARS-CoV-2 infection;
- Have received any COVID-19 vaccine;
- Participants with abnormal fasting blood glucose or diabetes;
- History of asthma, history of allergy to the vaccine or vaccine components,or serious adverse reactions to the vaccine, such as urticaria, dyspnea,and angioedema;
- Autoimmune disease or immunodeficiency / immunosuppression;
- Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;
- Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
- Thyroid disease or history of thyroidectomy, spleenlessness, functional spleenlessness, spleenlessness or splenectomy resulting from any condition;
- Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;
- Diseases or factors that are prone to thrombosis or bleeding, such as thrombophlebitis, major surgery/trauma, hereditary thrombotic disorder, sepsis, inflammatory bowel disease, severe varicose veins, May-Thurner syndrome, fibrinolytic activity enhancement disease, history of cardiac stent surgery, allergic purpura, etc.;
- Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
- Abnormal hematological laboratory test results outside the reference range during previous physical examination within one year: Blood routine indicators (white blood cell count, hemoglobin, platelet count), Coagulation function test (prothrombin time PT, activated partial prothrombin time APTT, fibrinogen FIB, thrombin time TT, international standardized ratio INR, D-dimer), other indicators (blood glucose, platelet factor 4 HIT ELISA, erythrocyte sedimentation rate);
- History of alcohol or drug abuse;
- Receipt of blood products within in the past 3 months;
- Receipt of other investigational drugs in the past 30 days;
- Receipt of attenuated live vaccines in the past 14 days;
- Receipt of inactivated or subunit vaccines in the past 7 days;
- Axillary temperature >37.0°C;
- Already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to get pregnant within 3 months;
- History of taking aspirin drugs and other drugs that affect blood coagulation;
- According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Group 23-valent pneumococcal polysaccharide vaccine 90 subjects (including 45 adults aged 18-59 years and 45 elderly aged 60 year and older）will receive one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of Inactivated Hepatitis A Vaccine on day 28 Experimental Group Inactivated COVID-19 Vaccine 180 subjects (including 90 adults aged 18-59 years and 90 elderly aged 60 year and older）will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28 Control Group Inactivated Hepatitis A Vaccine 90 subjects (including 45 adults aged 18-59 years and 45 elderly aged 60 year and older）will receive one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of Inactivated Hepatitis A Vaccine on day 28
- Primary Outcome Measures
Name Time Method Seroconversion rate of the neutralizing antibody to SARS-CoV-2 Day 28 after the second dose Seroconversion rate of the neutralizing antibody to SARS-CoV-2 at day 28 after the second dose of inactivated COVID-19 vaccine
- Secondary Outcome Measures
Name Time Method Seroconversion rate of the neutralizing antibody to SARS-CoV-2 Day 4, 14, 32,42 and 56 after the first dose Seroconversion rate of the neutralizing antibody to SARS-CoV-2 at different points after vaccination
Occurrence of abnormal changes of laboratory safety examinations Day 4, 14, 28, 32,42 and 56 after the first dose Occurrence of abnormal changes of laboratory safety examinations (Platelet factor 4 HIT, blood sugar, ESR, White blood cell count, hemoglobin, platelet count and Coagulation function index)
GMI of the hepatitis A antibody by Electrochemiluminescence Day 28 after vaccination of Inactivated Hepatitis A Vaccine GMI of the hepatitis A antibody at day 28 after vaccination of Inactivated Hepatitis A Vaccine
Seropositivity rate of the neutralizing antibody to SARS-CoV-2 Day 4, 14, 28, 32,42 and 56 after the first dose Seropositivity rate of of the neutralizing antibody to SARS-CoV-2 at different points after vaccination
GMI of the neutralizing antibody to SARS-CoV-2 Day 4, 14, 28, 32,42 and 56 after the first dose GMT of of the neutralizing antibody to SARS-CoV-2 at different points after vaccination
GMT of the neutralizing antibody to SARS-CoV-2 Day 4, 14, 28, 32,42 and 56 after the first dose GMT of of the neutralizing antibody to SARS-CoV-2 at different points after vaccination
Seroconversion rate of anti-pneumococcal antibody for 23 serotypes (ELISA) Day 28 after vaccination of 23-valent pneumococcal polysaccharide vaccine Seroconversion rate of anti-pneumococcal antibody for 23 serotypes (ELISA) at day 28 after vaccination of 23-valent pneumococcal polysaccharide vaccine
Geometric mean concentrations of anti-pneumococcal antibody for 23 serotypes (ELISA) Day 28 after vaccination of 23-valent pneumococcal polysaccharide vaccine Geometric mean concentrations of anti-pneumococcal antibody for 23 serotypes (ELISA) at day 28 after vaccination of 23-valent pneumococcal polysaccharide vaccine
Seropositivity rate of the hepatitis A antibody by Electrochemiluminescence Day 28 after vaccination of Inactivated Hepatitis A Vaccine Seropositivity rate of the hepatitis A antibody at day 28 after vaccination of Inactivated Hepatitis A Vaccine
GMT of the hepatitis A antibody by Electrochemiluminescence Day 28 after vaccination of Inactivated Hepatitis A Vaccine GMT of the hepatitis A antibody at day 28 after vaccination of Inactivated Hepatitis A Vaccine
Seroconversion rate of the hepatitis A antibody by Electrochemiluminescence Day 28 after vaccination of Inactivated Hepatitis A Vaccine Seroconversion rate of the hepatitis A antibody at day 28 after vaccination of Inactivated Hepatitis A Vaccine
Trial Locations
- Locations (1)
Rushan City Center for Disease Control and Prevention
🇨🇳Weihai, Shandong, China